SCHEMBL1242413

SCHEMBL1242413

CCCCCOc1ccc(-c2ccc(OC(F)(F)F)cc2)cc1N(Cc1ccccc1)C(=O)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 10/20 0.60
PTPN11 Q06124 3/20 0.41
LTB4R2 Q9NPC1 3/20 0.40
PTPN1 P18031 1/20 0.40
PTPN6 P29350 1/20 0.40
PSEN1 P49768 2/20 0.39
ALOX5 P09917 1/20 0.39
PPARD Q03181 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1242540 0.92 SERPINE1 (0.50) SERPINE1PTPN11LTB4R2PTPN1PTPN6
SCHEMBL1241578 0.91 SERPINE1 (0.49) SERPINE1PTPN11LTB4R2PTPN1PTPN6
SCHEMBL1241732 0.89 SERPINE1 (0.51) SERPINE1LTB4R2PSEN1ALOX5PPARD
SCHEMBL1241600 0.85 SERPINE1 (0.51) SERPINE1LTB4R2PSEN1ALOX5PPARD
SCHEMBL1239090 0.83 SERPINE1 (0.57) SERPINE1PSEN1ALOX5PPARD
SCHEMBL1241544 0.83 NR1H4 (0.41) SERPINE1PTPN11LTB4R2PTPN1PTPN6
SCHEMBL15434080 0.82 PDE4A (0.44) SERPINE1PTPN11PTPN1PTPN6PPARD
SCHEMBL13581023 0.82 PDE4A (0.44) SERPINE1PTPN11PTPN1PTPN6PPARD
SCHEMBL13580898 0.80 PDE4A (0.43) SERPINE1ALOX5PPARD
SCHEMBL1241446 0.80 NR1H4 (0.42) SERPINE1LTB4R2PPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7884234-B2 N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2011-02-08 US disclosed
US-20090215899-A9 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-08-27 US disclosed
EP-2072498-A1 N-PHENYLOXAMIDIC ACID DERIVATIVE Institute of Medicinal Molecular Design, Inc. (JP) 2009-06-24 EP disclosed
US-20080249175-A1 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249175-A1 N-Phenyloxamide derivatives SERPINE1, SERPINH1, F12 SERPINE1 1/4885PTPN11 2632/4885LTB4R2 1577/4885
US-20090215899-A9 N-Phenyloxamide derivatives SERPINE1, SERPINH1, F12 SERPINE1 1/4885PTPN11 2632/4885LTB4R2 1577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.